PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 13, 2026Egyptian Journal of Medical Human Genetics0 citationsOpen Access

Exploring the role of non-coding RNAs in retinoblastoma: mechanism of contribution, biomarker potential, therapeutic opportunities, and encountered challenges

View Full Paper
AAAlireza AzaniZMZahra MehrdadVGVahid Ghassemifar

Key Points

  • This research examines the role of non-coding RNAs in the progression and treatment of retinoblastoma.
  • Review of published studies on non-coding RNAs in retinoblastoma
  • Analysis of ncRNA classes like miRNAs, lncRNAs, and circRNAs
  • Assessment of biomarker potential and therapeutic opportunities
  • Identified contributions of long non-coding RNAs to tumor progression
  • Highlighted potential as diagnostic and prognostic biomarkers
  • Discussed challenges in targeting non-coding RNAs for treatment

Abstract

Abstract Retinoblastoma (RB) is a primary cancer of the eye that predominantly affects children, although rare adult cases have been reported. This malignancy arises from immature retinal cells and is a major cause of vision loss in the pediatric population. In advanced stages, RB can spread to the brain and other organs. The primary driver of this disease is mutations in the RB1 tumor suppressor gene; however, the full development and advancement of RB necessitate further genetic and epigenetic changes beyond RB1 inactivation. Epigenetic alterations in RB involve various mechanisms, with non-coding RNAs (ncRNAs) playing a crucial role in tumor progression. Dysregulation of various ncRNA classes, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), has been extensively documented, highlighting their contribution to the complexity and progression of the disease. The present study aims to collect a series of previously published studies exploring the contribution of ncRNAs in RB and their potential application as diagnostic and prognostic biomarkers, as well as considering them as valuable targets in the treatment of RB. It will also address the challenges encountered during this pathway.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Azani et al. (2026) studied this question.

synapsesocial.com/papers/6a03cb9d1c527af8f1ecf500https://doi.org/10.1186/s43042-026-00877-x
Ask AI
Helpful
Bookmark
Share
View Full Paper